Astellas Initiates Phase 3 Trial of Setidegrasib (ASP3082) in KRAS G12D-Mutated Metastatic Pancreatic Cancer, Dosing First Patient

Astellas Doses First Patient in Phase 3 Study of setidegrasib (ASP3082) for KRAS G12D-mutated Metastatic Pancreatic Ductal Adenocarcinoma Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that…

Read MoreAstellas Initiates Phase 3 Trial of Setidegrasib (ASP3082) in KRAS G12D-Mutated Metastatic Pancreatic Cancer, Dosing First Patient
Cabaletta

First Patients Receive Cabaletta Bio’s Rese-cel Produced Using Cellares’ Automated Cell Shuttle™ Platform

First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares’ Automated Cell Shuttle™ Platform Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.’s (“Cabaletta…

Read MoreFirst Patients Receive Cabaletta Bio’s Rese-cel Produced Using Cellares’ Automated Cell Shuttle™ Platform

VectorBuilder Launches High-Stability MuteFree™ AAV to Enhance Gene Therapy Manufacturing Reliability

VectorBuilder Introduces High-Stability MuteFree™ AAV to Improve Gene Therapy Manufacturing Reliability VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree™ AAV, a high-stability AAV vector…

Read MoreVectorBuilder Launches High-Stability MuteFree™ AAV to Enhance Gene Therapy Manufacturing Reliability